ContraFect (STU:22R) Short Percentage of Float


STU:22R ContraFect Corp STU:22R
28 GF Score
Price €4.98
View Full Analysis

What is ContraFect Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:22R vs ADTX, RUBY, NBY: Short Percentage of Float Comparison

For the Biotechnology subindustry, ContraFect's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ContraFect Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where ContraFect's Short Percentage of Float falls into.


STU:22R
28GF Score
ContraFect Corp STU:22R
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ContraFect Business Description

Address 28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
28GF Score

Get the complete analysis for STU:22R

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.98
Price